Should Patients on Ozempic Continue Their Oral Hypoglycemics?
Yes, patients starting Ozempic (semaglutide) should generally continue most oral hypoglycemic medications, but you must immediately reassess and reduce or discontinue sulfonylureas and meglitinides to prevent hypoglycemia. 1
Immediate Action Required: Hypoglycemia Risk Medications
When initiating semaglutide, the 2025 ADA guidelines explicitly state you must reassess the need for and/or dose of medications with higher hypoglycemia risk (i.e., sulfonylureas, meglitinides, and insulin) to minimize the risk of hypoglycemia and treatment burden 1. This is not optional—it's a critical safety measure that should happen at the time of semaglutide initiation.
Specific Medication Management:
Discontinue or significantly reduce:
- Sulfonylureas (glipizide, glyburide, glimepiride)
- Meglitinides (repaglinide, nateglinide)
These medications stimulate insulin secretion independent of glucose levels, and when combined with semaglutide's glucose-dependent insulin secretion, create substantial hypoglycemia risk 2.
Continue These Oral Medications
Metformin: Continue without dose adjustment. The guidelines support combination therapy, and metformin provides complementary benefits with different mechanisms 1.
SGLT2 inhibitors: Continue for their independent cardiovascular and renal protective effects, particularly if the patient has heart failure or CKD 3.
Pioglitazone: Can be continued and may even be beneficial if the patient has metabolic dysfunction-associated steatohepatitis (MASH) or is at high risk for liver fibrosis 1.
Absolutely Do NOT Continue
DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin): The guidelines are unequivocal—concurrent use of DPP-4 inhibitors with a GLP-1 RA is not recommended due to lack of additional glucose lowering beyond that of a GLP-1 RA alone 1. These medications work through the same incretin pathway and provide no additive benefit. Recent evidence confirms switching from DPP-4 inhibitors to semaglutide significantly improves glycemic control and reduces oxidative stress 4.
Clinical Algorithm for Medication Adjustment
At semaglutide initiation:
- Stop DPP-4 inhibitors immediately (no taper needed)
- Reduce sulfonylurea dose by 50% or discontinue entirely based on baseline A1C:
- If A1C <8%: discontinue
- If A1C 8-9%: reduce by 50%
- If A1C >9%: may continue initially but reassess within 2-4 weeks
- Continue metformin at current dose
- Continue SGLT2 inhibitors at current dose
- Continue pioglitazone if applicable
Monitor closely for 2-4 weeks and adjust further based on glucose readings.
Evidence Quality and Nuances
The 2025 ADA guidelines 1 represent the most current expert consensus and are reinforced by FDA labeling 2 that specifically warns about hypoglycemia risk when semaglutide is combined with insulin secretagogues. Real-world evidence demonstrates that semaglutide achieves HbA1c reductions of 1.1-1.4% 5, 6, which is substantial enough that maintaining full doses of sulfonylureas would create dangerous hypoglycemia risk.
Common Pitfalls to Avoid
Don't continue DPP-4 inhibitors "just in case"—this wastes money and adds no benefit while increasing pill burden 1.
Don't wait to reduce sulfonylureas—hypoglycemia can occur within days of starting semaglutide, particularly as the dose escalates from 0.25 mg to 0.5 mg and beyond 2.
Don't discontinue metformin or SGLT2 inhibitors—these provide complementary mechanisms and additional cardiometabolic benefits that semaglutide doesn't fully replicate 1, 3.
Ongoing Reassessment
Reevaluate the medication regimen every 3-6 months 1. As semaglutide improves glycemic control (typical HbA1c reduction 1.1-1.4% 5, 6), you may need to further adjust or discontinue other agents. The goal is achieving individualized glycemic targets while minimizing hypoglycemia risk, treatment burden, and cost.